Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business

This is a summary. Read the complete story at Yahoo Finance below.

Related Stories

marketsabout 5 hours ago

The case for Nvidia’s stock to march even higher after clinching its first record high in months

Analysts highlight the stock’s cheap valuation and the chip maker’s central role in the AI ecosystem.

MarketWatch

marketsabout 6 hours ago

This new AI model could help America close a technological gap with China

Nvidia-backed Reflection AI announced Beam, a new ultra-efficient open model that boasts capabilities on par with those of Chinese ones

MarketWatch

marketsabout 6 hours ago

Microsoft’s blazing stock comeback isn’t even close to being over, analyst says

Microsoft looks like a winning play in an environment where investors are looking for safer bets on the AI trend, according to Melius Research.

MarketWatch